# Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

> **NCT03085056** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 13 (actual)

## Conditions studied

- Anaplastic Thyroid Cancer

## Interventions

- **DRUG:** Trametinib
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03085056
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-03-15
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03085056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03085056, "Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03085056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*